“Together, we will manufacture and deliver a safe and effective vaccine to protect young children against the devastating consequences of meningococcal disease,” said Dr. Sven Bacher, president of BioNTech AG. “The Pfizer-BioNTech partnership brings together two organizations with deep expertise in pharmaceuticals and vaccines.”
BioNTech’ clinical vaccine candidates are based on messenger RNA (mRNA) technology and designed to express functional proteins that mimic the target structure of disease-causing microbes. The Company has demonstrated its vaccine platform and technologies in multiple clinical and pre-clinical studies,”This collaboration is an exciting new direction for the vaccine business that will enable us to provide an innovative option to protect children against meningococcal B disease,” said Dr. Rod MacKenzie, senior vice president of Pfizer’s vaccines business. “We are continuing our work on behalf of child health by exploring this novel technology with Bio
“This agreement builds upon Pfizer’s long-standing commitment to global public health,” said Dr. Thomas Breuer, senior vice president and chief medical officer, Vaccines, Oncology & Inflammation , Pfizer. “Pfizer is committed to helping reduce the burden of disease in children across the world through innovative partnerships like this one, by bringing our expertise and resources to enable the development of vaccines that matter.”
“For BioNTech this is a significant milestone in its journey towards developing novel therapeutics. We believe that this partnership will allow us to provide children around the world with an effective vaccine against meningococcal disease,” said Ugur Sahin, Ph.D., chairman and CEO, BioNTech.
Pfizer and BioNTech will work together to conduct preclinical research and development activities for therapeutic candidate vaccines for meningococcal B disease. Preclinical studies are expected to include: evaluation of vaccine safety and efficacy in animal models; determination of the optimal dosing regimen; characterization of the immunological profile of the vaccine candidate; and refinement of manufacturing processes. In addition, BioNTech will transfer at least two clinical stage programs to Pfizer for further development as part of its agreement with the company.
Pfizer is committed to helping reduce the burden of disease in children around the world through innovative partnerships, bringing its expertise and resources to bear in enabling the development of vaccines that matter.
BioNTech AG (Frankfurt, Germany) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies based on messenger RNA (mRNA). Unlike other gene transfer technologies, BioNTech’s approach delivers mRNA encoding for therapeutic proteins directly into cells. The company’s mRNA therapeutic platform can be harnessed for multiple clinical and preclinical programs: T cells, NK cells and B cells, as well as certain solid tumors. Building on this technology, BioNTech has identified a class of novel targets that it is currently developing into therapies.
Pfizer Inc. is a global pharmaceutical leader that discovers, develops, manufactures and delivers quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals.
My name is John P. Thomas and I am a writer for Health Impact News . The original source of this article is Activist Post – Reference: 1
The new availability of the information on Drs. Bradstreet and Tomljenovic-Shaw’s work is very significant because it has already been used by others to make an important discovery about vaccines, including We operate worldwide with the healthcare products and services businesses sector comprising commercial pharmaceuticals, consumer/generics, biopharmaceuticals, animal health, and corporate brands; and an emerging specialty business that includes the vaccine portfolio, tissue-based cancer therapeutics as well as consumer healthcare. Pfizer Inc.